Immunotech Laboraties in Discussions for Pre-"IND" Testing of Aids-HIV "IPF" Treatment in the USA
19 March 2013 - 12:00AM
Marketwired
Immunotech Laboratories, Inc. (PINKSHEETS:
IMMB) today announced the company has begun discussions with a
professional medical consulting group to start the process for
Pre-IND (Investigational New Drug) application in the USA.
This application could pave the way for Immunotech's patented
"IPF" Treatment to be submitted to the Food & Drug
Administration (FDA) for approval.
Information about the Pre-IND Purpose at:
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/Overview/ucm077546.htm
Link to Investigational New Drug Application
after Pre-Clinical Testing: (Example)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85055671
About Immunotech Laboratories Immunotech
Laboratories is a drug development company committed to the
commercialization of its proprietary proteins for the treatment of
debilitating infectious diseases such as HIV and Aids.
www.immunotechlab.com
Safe Harbor Statement: This news release
contains forward-looking statements that involve risks and
uncertainties associated with financial projections, budgets,
milestone timelines, clinical development, regulatory approvals,
and other risks described by Immunotech Laboratories, Inc. from
time to time in its periodic reports filed with the SEC. IPF is not
approved by the US Food and Drug Administration or by any
comparable regulatory agencies elsewhere in the world. While
Immunotech Laboratories believes that the forward-looking
statements and underlying assumptions contained therein are
reasonable, any of the assumptions could be inaccurate, including,
but not limited to, the ability of Immunotech Laboratories to
establish the efficacy of IPF in the treatment of any disease or
health condition, the development of studies and strategies leading
to commercialization of IPF in the United States, the obtaining of
funding required to carry out the development plan, the completion
of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that
the forward-looking statements included in this release will prove
to be accurate. In light of the significant uncertainties inherent
in the forward-looking statements included herein, Immunotech
Laboratories or any other person that the objectives and plans of
Immunotech Laboratories will be achieved should not regard the
forward-looking statements as a representation.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Company Contact: Email Contact Public Relations: The Nabors
Group: 713-875-9200 E-mail: Email Contact
www.facebook.com/Naborsgroup
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Immunotech Laborator (CE) (OTCMarkets): 0 recent articles
More Immunotech Laboratories Inc. News Articles